FourKites Launches Universal Time Slot Solution in Europe to Ease Supply Chain Labor Shortage Woes and Reduce Greenhouse Gas Emissions
6.4.2022 11:36:00 EEST | Business Wire | Press release
FourKites ®, the #1 real-time supply chain visibility platform, today launches Slot Manager, its universal time slot booking solution, across Europe. The cloud-based solution helps warehouses, distribution centers and manufacturing facilities collaborate efficiently on pickup and receiving time slots, saving significant time and improving daily operations and partner relationships. In addition, the highly configurable solution allows shippers and carriers to eliminate excess dwell time on site, eliminating detention fees and significantly reducing carbon emissions.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220406005544/en/
FourKites today launches Slot Manager, its universal time slot booking solution, across Europe. (Photo: Business Wire)
Time slot management is a notoriously time-consuming task for shippers and carriers alike. With carrier dwell averaging up to 4.35 hours per day, or nearly half of a driver’s time, Slot Manager improves facility productivity and reduces carrier wait time by more than 50%. Highly configurable for personalised requirements, Slot Manager enables shippers and carriers to collaborate in real time, and allows carriers to self-book their preferred time slot based on real-time transit conditions, thereby eliminating hours of daily administrative work and error-prone manual processes.
Slot Manager is an extension of FourKites’ Appointment ManagerSM, launched over two years ago. The solution is now also available in several new Asia-Pacific markets, including Australia, New Zealand and India.
Specifically, Slot Manager offers the following benefits:
- Labor optimisation: Leveraging FourKites’ Dynamic ETA® to provide the most accurate times of arrival, teams can better allocate labor and resources based on real-time data and shifts in expected arrival time.
- Ease and compliance with carrier scheduling: Slot Manager creates a single appointment layer accessible to both shippers and carriers to streamline communication and facilitate collaboration. Slots are created by the facility to ensure adherence to preferred scheduling, business rules and specific commodity requirements.
- True end-to-end visibility: Powered by real-time supply chain visibility data from FourKites, Slot Manager extends visibility even further into the facility via one streamlined interface. With FourKites, stakeholders receive a comprehensive end-to-end view of shipments from point of origin to predictive insights that help orchestrate activities in the facility.
- Diminished carrier detention costs: With optimised scheduling, carrier dwell on site can be virtually eliminated, helping shippers avoid detention fees and fines for truck queues on public roads.
- Reduced carbon emissions: Scheduling and operational efficiencies driven by Slot Manager reduce time carriers spend in the yard by up to 50%, cutting carbon dioxide emissions by an average of 54%.
“We are excited to introduce the easiest, most flexible slot booking application on the market,” said Mathew Elenjickal, FourKites Founder and CEO. “This groundbreaking solution helps shippers across the globe optimise end-to-end visibility, efficiency and sustainability, as well as adapt quickly as their business needs change. We’re thrilled to be launching Slot Manager in Europe, specifically tailored to the needs of local facilities.”
In addition, FourKites has partnered with French transportation solutions firm IER, a Blue Systems entity (Bolloré Group), to facilitate integrated implementation in Europe, driving greater efficiency for both carriers and facilities. The partnership combines IER’s leading standard of facility hardware technology with facility processes for automated check-in and check-out. When combined with FourKites’ advanced data capture and processing capabilities, the companies’ combined pre-configured integration offers a fast, turnkey facility solution for customers.
"We chose to partner with FourKites due to their globally recognised data quality and their commitment to delivering that data back to customers with actionable insights," said Christophe Levy, Chief Executive Officer of IER’s Track & Trace Unit. "By combining FourKites’ advanced supply chain intelligence capabilities with our leading facility hardware capabilities, we offer a seamlessly integrated solution that helps customers achieve immediate results for their business."
About FourKites
FourKites® is the #1 supply chain visibility platform in the world, extending visibility beyond transportation into yards, warehouses, stores and beyond. Tracking more than 2.5 million shipments daily across road, rail, ocean, air, parcel and courier, and reaching more than 185 countries, FourKites combines real-time data and powerful machine learning to help companies digitise their end-to-end supply chains. More than 1,000 of the world’s most recognised brands — including 9 of the top-10 CPG and 18 of the top-20 food and beverage companies — trust FourKites to transform their business and create more agile, efficient and sustainable supply chains. To learn more, visit https://www.fourkites.com/.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220406005544/en/
Contact information
Scott Johnston | FourKites European PR Director | scott.johnston@fourkites.com | +31 62 147 8442
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
